Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart oxygen device aims to free lung patients from constant monitoring

NCT ID NCT07704567

Symptom relief Sponsor: Minnesota HealthSolutions Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This study tests a lightweight, battery-powered device called MoblO2 that automatically adjusts oxygen flow to keep blood oxygen levels steady during activity. It is designed for people with COPD or interstitial lung disease who need supplemental oxygen when exerting themselves. The goal is to see if the device helps them be more active, use oxygen more efficiently, and improve their quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MoblO2 device, a closed-loop oxygen delivery regulator that automatically adjusts oxygen flow based on pulse oximeter readings
What this could lead to
If successful, this device could make supplemental oxygen easier to use, reduce the need for constant monitoring, and improve quality of life for people with chronic lung disease.
What could go wrong
This is a small, early-stage study with 48 participants, so results may not apply to everyone. The device may not work as intended in all situations, and technical failures or battery issues could pose risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 95 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Previously-diagnosed COPD or chronic interstitial lung disease Prescribed O2 for use with exertion at least 1 month prior to enrollment Age 25 years old or greater Self-reported stable symptoms and stable oxygen needs for at least 2 weeks Consent to using compressed gas tanks to deliver O2 during the 2-week study period Exclusion Criteria: Active angina Musculoskeletal disease that precludes physical activity Need for O2 at rest Patient needing more than 10 L/min continuous flow with exertion on O2 screen Patient prescribed 10L/min continuous flow (or more) by their prescribing practitioner

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD, chronic obstructive pulmonary disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD, chronic obstructive pulmonary disease Intersitital lung disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Jewish Health

    RECRUITING

    Denver, Colorado, 80206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.